Month: May 2023

Double-Digit Revenue and Operating Profit GrowthHighest Q1 GAAP Operating Profit Margin Since 2018, Non-GAAP Operating Profit Margin Since 2010Increased Full-Year 2023 Guidance for Operating Profit, Adjusted EBITDA and EPS Q1 Highlights:Revenue up 10%, reflecting 13% organic growth Operating profit: GAAP up 28% to $80M; non-GAAP up 14% to $127M Operating margin: GAAP up 16% to 6.7%; non-GAAP up 3% to 10.7% GAAP net income down 79% to $15M; adjusted EBITDA up 15% to $191M EPS: GAAP $0.30; non-GAAP $1.16RICHMOND, Va., May 10, 2023 (GLOBE NEWSWIRE) —  The Brink’s Company (NYSE:BCO), the global leader in total cash management, route-based secure logistics and payment solutions, today announced first-quarter results. Mark Eubanks, president and CEO, said: “Our strong performance in the first quarter demonstrates continued positive...

Immunocore Reports First Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £42.1 million ($52.0 million) in Q1 2023, with continued commercial expansion Randomization started in Phase 2/3 trial with KIMMTRAK in previously–treated, advanced melanoma Patients continue to enroll in monotherapy and combination arms of IMC-F106C (PRAME-HLA-A02) Phase 1/2 trial Enrolling people living with HIV in multiple ascending dose part of IMC-M113V Phase 1 trial Cash and cash equivalents increased to £337 million ($417 million) as of March 31, 2023 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 10 May 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed...

NEW YORK, May 10, 2023 (GLOBE NEWSWIRE) — 1stdibs.com, Inc. (NASDAQ: DIBS), a leading online marketplace for luxury design products (“1stDibs” or the “Company”), today reported financial results for its first quarter ended March 31, 2023. First Quarter 2023 Financial HighlightsNet revenue was $22.2 million, a decrease of 17% year-over-year. Gross profit was $14.9 million, a decrease of 21% year-over-year. Gross margin was 67.1%, compared to 71.1% in the first quarter 2022. GAAP net loss was $8.1 million compared to a net loss of $6.4 million in the first quarter 2022. Non-GAAP Adjusted EBITDA and Adjusted EBITDA Margin was $(5.3) million and (23.7)%, respectively, compared to $(4.7) million and (17.6)%, respectively, in the first quarter 2022. Cash, cash equivalents and short-term investments totaled $150.5 million...

TORONTO, May 10, 2023 (GLOBE NEWSWIRE) — Rivalry Corp. (the “Company” or “Rivalry”) (TSXV: RVLY) (OTCQX: RVLCF) (FSE: 9VK), an internationally regulated sports betting and media company, today announced details of its planned release of first quarter 2023 financial results. The Company expects to file its Q1 2023 results the morning of Wednesday, May 24, 2023 prior to the commencement of TSXV trading. Management plans to host an investor conference call that same day at 10:00 am EDT to discuss the results. Conference Call DetailsTiming:   Wednesday, May 24, 2023 at 10:00 am EDT     Dial-in:    888-886-7786 (toll free) or (+1) 416-764-8658 (local or international calls)     Webcast:    A live webcast can be accessed from the Events section of the Company’s website at www.rivalrycorp.com or at this link.A replay...

Entered into partnership with Amgen to identify novel targets in Crohn’s disease; TScan to receive $30 million upfront Enrolled patients in all three arms of Phase 1 hematologic malignancies study; TSC-101 progressing to second dose level Announced upcoming trial-in-progress poster presentation on 5/17 at ASGCT, followed by call at 5:30 p.m. ET Appointed Barbara Klencke, M.D., to Board of Directors Ended 1Q 2023 with cash and cash equivalents of $95.6 million, which combined with Amgen partnership extends cash runway into 3Q 2024 WALTHAM, Mass., May 10, 2023 (GLOBE NEWSWIRE) — TScan Therapeutics, Inc. (Nasdaq: TCRX) (“TScan” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today reported...

– $412 million in cash, cash equivalents and marketable securities as of March 31, 2023 –– Cash runway into the second half of 2025 – BOSTON, May 10, 2023 (GLOBE NEWSWIRE) — Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today reported financial results for the first quarter ending March 31, 2023, and highlighted recent business updates. “In the first quarter, we successfully closed on our transformational collaboration with Vertex for the development of EEV-therapeutics targeting myotonic dystrophy type 1, the most prevalent form of muscular dystrophy. In addition to advancing this important program, the collaboration provides validation...

SOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) — Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today reported first quarter 2023 financial results and provided business updates. “Finch has continued to execute on its strategy to advance its novel microbiome technology through partnerships and collaborations, highlighted by the recent investigator-sponsored clinical trial agreement with Brigham and Women’s Hospital to evaluate CP101 for the treatment of ulcerative colitis and an amended license agreement with the University of Minnesota,” said Mark Smith, PhD, Chief Executive Officer of Finch Therapeutics. “I am also pleased to welcome Matthew Blischak and Lance Thibault, Finch’s incoming...

Report on the first quarter of 2023for ROCKWOOL A/SRelease no. 07 – 2023to Nasdaq Copenhagen 10 May 2023 Satisfactory first quarter earnings in a difficult market with low construction activity HighlightsSales in Q1 2023 reached 866 MEUR, a decrease of seven percent in local currencies and six percent in reported figures compared to last year, driven by lower demand in most markets. EBITDA in Q1 2023 reached 164 MEUR, an increase of six percent in reported figures compared to Q1 2022. The EBITDA margin was 18.9 percent, up 2.1 percentage points from last year. The lower volume was partly offset by higher sales price in a quarter with moderate inflation. EBIT increased two percent to 104 MEUR in Q1 2023, with a 12.0 percent EBIT margin, up 1.0 percentage point from Q1 2022. EBIT included a 13 MEUR donation to the Foundation for Ukrainian...

– Phase I/IIa clinical trials in NSCLC and melanoma progressing with additional clinical and translational science data expected in the fourth quarter of 2023 – – Strong cash position of $158.5 million supports operations into mid-2025 –         LONDON, May 10, 2023 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2023, and recent business highlights. “We continue to make progress in our ongoing Phase I/IIa clinical trials evaluating our clonal neoantigen-reactive T cell (cNeT) therapy for the treatment of advanced NSCLC (CHIRON) and metastatic malignant melanoma (THETIS). Additionally,...